期刊
ACTA PHARMACOLOGICA SINICA
卷 44, 期 1, 页码 8-18出版社
NATURE PUBL GROUP
DOI: 10.1038/s41401-022-00934-2
关键词
O-GlcNAcylation; glycomics; glycosylation; cardiovascular disease
O-GlcNAcylation is a protein post-translational modification controlled by O-GlcNAc transferase (OGT) and protein O-GlcNAcase (OGA), and is involved in the development of cardiovascular disease (CVD). Changes in O-GlcNAcylation levels can disrupt metabolic balance and affect cardiovascular function, but its role in CVD is still controversial. This review focuses on the interactions between protein O-GlcNAcylation and CVD and discusses potential molecular mechanisms for the treatment of cardiovascular events.
O-GlcNAcylation is a post-translational modification of protein in response to genetic variations or environmental factors, which is controlled by two highly conserved enzymes, i.e. O-GlcNAc transferase (OGT) and protein O-GlcNAcase (OGA). Protein O-GlcNAcylation mainly occurs in the cytoplasm, nucleus, and mitochondrion, and it is ubiquitously implicated in the development of cardiovascular disease (CVD). Alterations of O-GlcNAcylation could cause massive metabolic imbalance and affect cardiovascular function, but the role of O-GlcNAcylation in CVD remains controversial. That is, acutely increased O-GlcNAcylation is an adaptive heart response, which temporarily protects cardiac function. While it is harmful to cardiomyocytes if O-GlcNAcylation levels remain high in chronic conditions or in the long run. The underlying mechanisms include regulation of transcription, energy metabolism, and other signal transduction reactions induced by O-GlcNAcylation. In this review, we will focus on the interactions between protein O-GlcNAcylation and CVD, and discuss the potential molecular mechanisms that may be able to pave a new avenue for the treatment of cardiovascular events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据